Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Incidence and Risk Factors of Acute Kidney Injury (AKI) After Anti-CD19 CAR-T Cells Treatments in B-cell Lymphoma and Long Term Evolution.

NCT07101913 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT07101913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07101913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Incidence and Risk Factors of Acute Kidney Injury (AKI) After Anti-CD19 CAR-T Cells Treatments in B-cell Lymphoma and Long Term Evolution.
Lead sponsor
Hospices Civils de Lyon
Phase
Observational
Overall status
Active, not recruiting
Start date
April 1, 2025
Completion date
April 1, 2026
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury (aki), b cell lymphoma, infusion of cd19 car t cell